Antibody Information

General Information of This Antibody
Antibody ID
ANI0IZQGT
Antibody Name
Bevacizumab
Brand Name
AVASTIN
Organization
Genentech, Inc.; Chugai Pharmaceutical Co., Ltd.; F. Hoffmann-La Roche Ltd.
Indication
Non-small cell lung cancer; Colorectal cancer; Renal cell carcinoma; Glioblastoma; Breast cancer; Cervical cancer; Mesothelioma
Approval Date
Feb. 2004
Synonyms
12-IgG1; F(ab)-12 IgG1; Fab-12 IgG1; rhuMAb-VEGF; ABP-215; ALYMSYS; 12-IGG1; ABP-215; ALYMSYS; AVA-1; BAT1706; BAT 1706; BAT-1706; BEVACIZUMAB; BEVACIZUMAB AWWB; BEVACIZUMAB-AWWB; BEVACIZUMAB BETA; BEVACIZUMAB BIOSIMILAR (FKB-238); BEVACIZUMAB BVZR; BEVACIZUMAB-BVZR; BEVACIZUMAB MALY; BEVACIZUMAB-MALY; BI695502; BI 695502; BI-695502; BS-503; BS-503A; BYVASDA; CHS-5217; CT-16; CT-P16; CT-P16 (BIOSIMILAR OF BEVACIZUMAB); FKB238; FKB 238; FKB-238; HLX04; HLX 04; HLX-04; IBI305; IBI-305; LY 01008; LY-01008; MVASI; PF-06439535; Q1101; Q-1101; R-435; RG-435; RHUMAB; RHUMAB-VEGF; USP MAB 002, MONOCLONAL IGG1; ZIRABEV; AVASTIN
   Click to Show/Hide
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Humanized IgG1-kappa
Antigen Name
Vascular endothelial growth factor A (VEGFA)
  Antigen Info 
ChEMBI ID
CHEMBL1201583
PDB ID
1bj1 , 6bft
DrugBank ID
DB00112
Drug Central ID
4956
Click to Show/Hide the Sequence Information of This Antibody
Heavy Chain Sequence
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTY
AADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVT
VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEL
LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE
QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    Click to Show/Hide
Heavy Chain Varible Domain
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTY
AADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVT
VSS
    Click to Show/Hide
Heavy Chain Constant Domain 1
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV
    Click to Show/Hide
Heavy Chain Constant Domain 2
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK
    Click to Show/Hide
Heavy Chain Constant Domain 3
GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    Click to Show/Hide
Heavy Chain Hinge Region
EPKSCDKTHTCPPCP
    Click to Show/Hide
Heavy Chain CDR 1
GYTFTNYG
    Click to Show/Hide
Heavy Chain CDR 2
INTYTGEP
    Click to Show/Hide
Heavy Chain CDR 3
AKYPHYYGSSHWYFDV
    Click to Show/Hide
Light Chain Sequence
DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPS
RFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
    Click to Show/Hide
Light Chain Varible Domain
DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPS
RFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK
    Click to Show/Hide
Light Chain Constant Domain
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
    Click to Show/Hide
Light Chain CDR 1
QDISNY
    Click to Show/Hide
Light Chain CDR 2
FTS
    Click to Show/Hide
Light Chain CDR 3
QQYSTVPWT
    Click to Show/Hide
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Bevacizumab vedotin [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.14 ug/mL
Positive VEGFA expression (VEGFA +++/++)
Method Description
The anti-proliferative activity of Bevacizumab Vedotin and Bevacizumab against three different cell lines was determined by MTT method.
In Vitro Model Invasive breast carcinoma MCF-7 cells CVCL_0031
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.65 ug/mL
Positive VEGFA expression (VEGFA +++/++)
Method Description
The anti-proliferative activity of Bevacizumab Vedotin and Bevacizumab against three different cell lines was determined by MTT method.
In Vitro Model Hepatoblastoma Hep-G2 cells CVCL_0027
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
14.17 ug/mL
Positive VEGFA expression (VEGFA +++/++)
Method Description
The anti-proliferative activity of Bevacizumab Vedotin and Bevacizumab against three different cell lines was determined by MTT method.
In Vitro Model Glioblastoma U-87MG cells CVCL_0022
References
Ref 1 Discovery of novel antibody-drug conjugates bearing tissue protease specific linker with both anti-angiogenic and strong cytotoxic effects. Bioorg Chem. 2023 Aug;137:106575. doi: 10.1016/j.bioorg.2023.106575. Epub 2023 Apr 26.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.